Overview

An Evaluation of the Adrenal Suppression Potential and Pharmacokinetic Properties of CB-03-01 Cream in Subjects With Acne Vulgaris

Status:
Completed
Trial end date:
2013-11-01
Target enrollment:
Participant gender:
Summary
This study is designed to determine the hypothalamic-pituitary-adrenal (HPA) axis suppression potential and pharmacokinetic (PK) properties of CB-03-01 Cream, 1%, applied every twelve hours for two weeks, in subjects with acne vulgaris ages 12 years or older.
Phase:
Phase 2
Details
Lead Sponsor:
Intrepid Therapeutics, Inc.